Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European health care systems. Newborn screening (NBS) for SCD enables early initiation of preventive measures and has contributed to a reduction in childhood mortality from SCD. Policies and methodologies for NBS vary in different countries, and this might have consequences for the quality of care and clinical outcomes for SCD across Europe. A two-day Pan-European consensus conference was held in Berlin in April 2017 in order to appraise the current status of NBS for SCD and to develop consensus-based statements on indications and methodology for NBS for SCD in Europe. More than 50 SCD experts from 13 European countries participated in the conference. This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development of NBS programmes in European countries where they do not yet exist, and to review existing programmes.
Introduction
Sickle Cell Disease (SCD) is an autosomal recessive inherited blood condition that has recently been reviewed elsewhere (Piel et al, 2017; Ware et al, 2017) . Briefly, the sickle mutation causes a substitution of valine for glutamic acid at position 6 of the beta globin chain. This results in a defective haemoglobin molecule (HbS) that can aggregate and form polymers with adjacent haemoglobin molecules when in the deoxygenated state. As a consequence, red blood cells become damaged by polymerised HbS. Repeated cycles of polymerisation-depolymerisation damage the erythrocyte cytoskeleton and cell membrane, leading to a decrease in erythrocyte lifespan that is clinically apparent as haemolysis and its sequelae. There is also defective flow of red blood cells in the microcirculation resulting in occlusion of capillaries and postcapillary venules. Haemolytic and vaso-occlusive phenomena give rise to vascular remodelling and large vessel complications. Both, acute infarctions and large vessel disease cause progressive life-limiting organ damage.
Complications of vaso-occlusion include dactylitis (painful swelling to the hands and/or feet), acute pain episodes, acute chest syndrome and others. Children with SCD are particularly prone to Invasive Pneumococcal Disease (IPD) as a result of functional hypo-/asplenia (Overturf et al, 1977; Powars et al, 1983; Wong et al, 1992a; Payne et al, 2013) . Other causes of morbidity and mortality include acute anaemia secondary to splenic sequestration, parvovirus B19 infection and malaria (in endemic regions) (Ballas et al, 2010) . Complications of SCD result in frequent hospitalization for treatment, which is burdensome for health care systems (Brozovic et al, 1987; Colombatti et al, 2008; Lanzkron et al, 2010; Raphael et al, 2013; BouMaroun et al, 2018) .
Globally, SCD is among the most commonly inherited disorders. Every year, more than 300Á000 babies are born with SCD, the majority in Sub-Saharan Africa and in India (Piel et al, 2013 (Piel et al, , 2016 Serjeant, 2017; Ware et al, 2017) . Although morbidity and mortality rates in affected children from these regions are very high (Grosse et al, 2011; Makani et al, 2011) , outcomes have been dramatically improved in higher income countries by implementation of early preventive measures and improvements in comprehensive care (Gaston et al, 1986; Vichinsky et al, 1988; Quinn et al, 2010; Le et al, 2015; Couque et al, 2016) . Life-threatening early complications of SCD can be reduced by parental education and preventive medical interventions (Quinn et al, 2010; Wang et al, 2011; Yawn et al, 2014;  Consensus on NBS for SCD in Europe ª 2018 British Society for Haematology and John Wiley & Sons Ltd Couque et al, 2016) . Both Pneumococcal prophylaxis with oral penicillin from 3 months of age and pneumococcal vaccination significantly reduce the risk of IPD (Overturf & Powars, 1980; Gaston et al, 1986; Wong et al, 1992b; Falletta et al, 1995; Sobota et al, 2015; Rankine-Mullings & Owusu-Ofori, 2017) . Parents can be taught how to recognise signs and symptoms of anaemia, and how to examine for splenic enlargement so that they can bring the child to medical attention promptly and avoid adverse outcomes from acute splenic sequestration (Wang et al, 2011) . These observations have helped to support inclusion of SCD in the newborn screening (NBS) programmes of several European countries (Table I and II) .
There are two alternative approaches to NBS. "Targeted screening" takes the ethnic ancestry of every newborn into account. Testing is restricted to babies whose parental family origins are from 'at risk' ethnic groups. In contrast, "universal screening" is offered to the whole newborn population irrespective of family origins.
In its publication "A Roadmap for European Haematology Research" (Engert et al, 2016) , the European Haematology Association (EHA) recommended undertaking detailed epidemiological studies in all countries, particularly in Western Europe, as a prerequisite for the implementation of effective prevention programmes. Previously, there have been efforts to develop uniform standards for care of SCD across Europe (de Montalembert et al, 2011; Engert et al, 2016) , but significant variation in practice persists. Two factors have recently highlighted the need for a more coordinated approach to diagnosis and management. Firstly, the globalization of migration flows has increased cultural diversity, bringing to Europe populations from areas with high prevalence of SCD and increasing the number of patients (Roberts & de Montalembert, 2007; Piel, 2016; Cortes-Castell et al, 2017; Inusa & Colombatti, 2017; Kunz et al, 2017) . Secondly, health policies and health systems across the European Union (EU) are becoming increasingly interconnected, because of patients receiving healthcare across the EU, health professionals working in different EU countries, higher expectations for healthcare and new developments in health technologies (EU 2011) . The "Pan-European Consensus Conference on Newborn Screening for Haemoglobinopathies", which took place in Berlin, Germany on 29-30 April 2017, brought together more than 50 experts with both laboratory and clinical backgrounds from 13 European countries; it was endorsed by EuroBloodNet, the European Reference Network (ERN) in Rare Haematological Diseases (www.eurobloodnet.com).
The conference had two major goals:
1 To provide an overview of current NBS policies and epidemiological data across Europe. 2 To identify key questions from both laboratory and clinical perspectives that relate to implementing and sustaining NBS programmes in Europe, and to attempt to reach a consensus statement on each of these questions.
The purpose of this paper is to report a summary of the data discussed at the conference and to present the consensus statements.
Methodology
The idea of a European meeting to address priorities for SCD was first suggested at the Global Sickle Cell Disease Network (GSCDN) meeting in Rio de Janeiro, Brazil, 11-14 November 2014, and further developed at the 10th Annual Conference of the Academy of Sickle Cell and Thalassaemia (ASCAT) in London, 5-7 October 2016. NBS was suggested as the first issue to be addressed, being the first specific intervention after birth.
Four months before the conference, clinical and laboratory experts in the field of SCD from European countries where SCD is considered a health care issue were invited to participate. Experts were selected on the basis of their publications and/or presentations at scientific meetings. They were joined by representatives from national scientific societies, national SCD reference centres and national NBS programmes. Streetly (2000 Streetly ( , 2005 Streetly et al (2008, 2010, 2018) Please note: The UK has a linked antenatal and neonatal screening programme for haemoglobinopathies. Cyprus and Turkey have antenatal programmes only (Angastiniotis & Hadjiminas, 1981; Kolnagou & Kontoghiorghes, 2009; Canatan, 2014; Kountouris et al, 2016) .
The steering committee (RC, EC, JE, SL) prepared a standardized form for the presentation of each country's national data on NBS (Appendix S1) that was sent to the speakers 1 month in advance of the conference. The committee also drafted a list of questions for consensus discussion (Appendix S2). On the first day of the conference, key topics in epidemiology, screening and NBS techniques were reviewed. Representatives from 12 countries (Cyprus, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, UK) then reported available data on NBS for haemoglobinopathies in their countries (agenda available in Appendix S3).
On the second day, consensus questions were discussed and experiences of NBS for SCD outside Europe were explored. The discussion was moderated by an independent non-European specialist (KOF) who was assisted by a patient representative (JJ).
Results

National policies and country presentations
National screening policies were found to be quite heterogeneous across European countries, and data on the number of affected patients were not available for every country. Moreover, there was no standardized approach to defining the population to be screened, the screening methodology and the flow of samples and patient reports.
England, Wales, Scotland, Northern Ireland , France (Bardakdjian-Michau et al, 2009; Couque et al, 2016) , Spain (Manu Pereira & Corrons, 2009; Cela et al, 2017) and the Netherlands (Bouva et al, 2010; Jans et al, 2012) have established national NBS programmes for SCD. In Belgium, a regional screening programme has operated in Brussels and the surrounding areas since 1994 and in Li ege and the surrounding areas since 2002 (Gulbis et al, 2009) . Germany Lobitz et al, 2014; Grosse et al, 2016; Kunz et al, 2016) , Ireland (Gibbons et al, 2015) and Italy (Ballardini et al, 2013; Rolla et al, 2014; Lodi et al, 2017; Martella et al, 2017) , reported completed pilot studies. Some countries have reported a reduction in mortality and SCDrelated complications (Telfer et al, 2007; van der Plas et al, 2011; Le et al, 2018) and economic benefits for their health care systems (Okpala et al, 2002; Castilla-Rodr ıguez et al, 2016; Streetly et al, 2018) .
Haemoglobinopathy programmes in Turkey and Cyprus are aimed at prevention and are based on premarital screening and prenatal diagnosis (Angastiniotis & Hadjiminas, 1981; Canatan, 2014; Kountouris et al, 2016) . A few countries with evidence of increasing numbers of patients have not yet considered planning national strategies. Table I and II provides an overview of the status quo of NBS for SCD in Europe. Detailed data presented by country representatives are summarized in Table III and IV.
Consensus questions and statements
Do you agree that the future burden of SCD in Europe will be increasing? It was undisputed that the burden of SCD in Europe has been increasing and is likely to continue to do so in the foreseeable future (Piel, 2016) . This increase is due to three factors: (i) an increase in the number of newborns (Piel et al, 2013) ; (ii) an increase in life expectancy of SCD (Quinn et al, 2010; Le et al, 2015; Gardner et al, 2016) and (iii) an increase in the number of immigrants with SCD from areas of high prevalence (Inusa & Colombatti, 2017; Kunz et al, 2017) .
These three factors make a variable contribution to the burden of SCD in different European countries. For example, in Spain, the number of SCD patients increased significantly 10-15 years ago as a result of immigration from Africa, but appears to have stabilized in the past few of years (Cela et al, 2017) . In contrast, Italy, France and Germany have recently been accepting large numbers of refugees and have faced a dramatic increase in their patient numbers since 2014. In England, where there is a well-established linked newborn and antenatal screening programme for SCD and thalassaemia, a downward trend in reported screen positive results 
(registry) (registry) *Please note: In all participating countries virtually 100% of newborns are tested for endocrine and metabolic diseases. However, the target diseases vary from country to country. is discernible in some areas (National Health Service [NHS] 2018). However, total patient numbers continue to increase due to the improved life expectancy attributed to the success of the national disease management programme and awareness campaigns (Gardner et al, 2016) . Many epidemiological questions on SCD remain unanswered due to the lack of standardized national data collection systems across Europe. A European Haemoglobinopathy Registry could enhance monitoring of changing demographics, service delivery and patient outcomes, and improve patient access to care (Inusa & Colombatti, 2017) . Of the countries that participated in the conference, national registries for SCD exist in Belgium, Cyprus, Germany, Greece, Spain and the UK (Cela et al, 2017; Kountouris et al, 2016; Kunz et al, 2017; Le et al, 2015; Voskaridou et al, 2012;  http://nhr.mdsas.com/).
Consensus statements
1a. In Europe the burden of Sickle Cell Disease (SCD) has increased and will continue to increase. 1b. It is desirable that all European patients with SCD are enrolled onto registries, with standardized data collection and coordinated follow-up.
What are the target diseases in a NBS programme for haemoglobinopathies? The panel noted that there was good evidence for the benefit of detecting SCD at birth and was unanimous that SCD (all genotypes) should be the primary target disease of a NBS programme. Although there was insufficient evidence of a clinical benefit in diagnosing beta thalassaemia major in newborns, the panel supported the recommendation that a suspected diagnosis should be reported to the family. This consensus takes into account that beta thalassemia major will be detected as a "by-product" of most test methods ("F only pattern"). All panel members agreed that it is advantageous to detect thalassaemia major early in order to counsel and prepare the family for the care of a sick child.
2a. The target disease of a NBS programme for haemoglobinopathies is SCD, including all genotypes. 2b. Beta thalassaemia, whilst not a formal target disease of a NBS programme for haemoglobinopathies, should also be reported.
What are the benefits of an early detection of SCD? The panel noted good evidence that early detection of SCD reduces morbidity and mortality. In particular, IPD can be reduced by pneumococcal vaccination and early initiation of prophylactic oral penicillin (Quinn et al, 2010; Le et al, 2015; Sobota et al, 2015; Couque et al, 2016; Gaston et al, 1986) . This benefit of early detection may have reduced in recent years because children in most European countries receive conjugate pneumococcal vaccinations as part of routine infant vaccination schedules. However, strains not included in the vaccine remain a problem, which may worsen in the future (Payne et al, 2013; Tin Tin Htar et al, 2015; Waight et al, 2015; Camilli et al, 2017; Latasa Zamalloa et al, 2017; Oligbu et al, 2018) . Antibiotic prophylaxis therefore remains necessary. Morbidity and mortality due to infections, acute anaemic episodes and vaso-occlusive events, such as acute chest syndrome, can be further reduced by parental education and clear pathways for accessing care and effective treatment protocols (Olney, 1999; Serjeant et al, 2018) . The incidence of childhood stroke can also be reduced by about 90% through transcranial Doppler (TCD) screening from 2 years of age and transfusion of children with confirmed abnormal transcranial Doppler velocities (Adams et al, 1992 (Adams et al, , 1998 Adams & Brambilla, 2005) . The panel agreed that a NBS programme must be accompanied by a comprehensive care programme for affected infants. This requires a sufficient number of centres to provide access to comprehensive care, together with awareness campaigns and patient involvement throughout the geographical region of screening. A treatment guideline adapted to national specifics is desirable. However, as several guidelines are available in Europe, including a European recommendation on comprehensive care for children with SCD (de Montalembert et al, 2011), the presence of a national guideline is not mandatory.
Consensus Statement
Early diagnosis by NBS, together with anti-pneumo-
coccal penicillin prophylaxis and vaccination, coordinated follow-up and parental education, reduces morbidity and mortality from SCD in childhood.
Which countries should screen for SCD? The panel agreed that it is not necessary to define a threshold of birth prevalence that would be required for the implementation of NBS for SCD. Nevertheless, epidemiological data should be available to support the decision to implement NBS screening (e.g. pilot studies, registry) and cost-effectiveness should be evaluated (Davies et al, 2000; Grosse et al, 2005; CastillaRodr ıguez et al, 2016; Kuznik et al, 2016) . The panel acknowledged that it is not possible to detect SCD as a by-product of tests currently used in NBS for metabolic or endocrine target diseases. NBS for SCD requires the addition of a further testing methodology to the existing NBS programme.
In principle, any screening programme should be costeffective. There is evidence from the literature that cost-effectiveness of NBS for SCD is reached if the birth prevalence is in the order of 1:6000 births (Castilla-Rodr ıguez et al, 2016). However, other factors, such as organization of the screening programme (centralised versus de-centralised infrastructure), screening method and effectiveness of health care measures (Grosse, 2015) , could also determine cost-effectiveness. Each screening programme should be periodically evaluated to ascertain its benefits.
Consensus statements
4a. The implementation of a national NBS programme for SCD should be informed by a review of national epidemiological data on SCD, but should not be based solely on a threshold birth prevalence. Where not available, these data should be collected. 4b. A NBS programme should be developed and implemented alongside a national disease management strategy.
Who should be screened? This question aimed to obtain a consensus on whether to screen all newborns ("universal NBS") or only those newborns considered to be at risk on the basis of ethnic origin ("targeted NBS"). The panel agreed that NBS for SCD should be universal, i.e. all newborns should be screened independent of their putative ethnic origin. Targeted screening is error-prone (Thuret et al, 2010 ) and could result in stigmatization of certain individuals from at-risk ethnic groups. Missed cases (false negatives) result from incorrectly assigning a parent to a low-risk ethnic group, failure to consider more distant ancestral origins, or to a range of administrative errors (Grosse, 2015) . In countries where SCD is rare, health care professionals may not be aware of the individual risk for a couple. Language barriers may be another source of error, particularly for parents from at-risk immigrant populations in Europe who may not be familiar with the language of the new country. Considering the disadvantages of targeted screening approaches, the panel urges health care teams involved with antenatal and neonatal care to evaluate newborns on a case-by-case basis (carefully considering the family history) if there is no NBS programme in place.
In countries where all pregnant women are offered carrier testing (antenatal screening), universal NBS may be considered unnecessary. However, in practice, linkage of antenatal screening and NBS is operationally challenging. Furthermore, deficiencies in the antenatal screening pathway, such as failure to notify and counsel the mother of a positive carrier screening result, could impact the offer of NBS and result in failure to identify an affected infant.
5a. The panel recommends universal NBS screening for SCD in all countries participating in the conference. 5b. Targeted screening based on ethnic origins is not recommended because of the higher risk of failure to identify an affected newborn. 5c. In countries where national NBS screening for SCD is not implemented, an interim policy should be agreed for testing at-risk newborns on a case-by-case basis according to family origins.
Should carriers identified in NBS be informed about their result? The carrier status (HbAS) is not completely harmless and is a risk factor for several complications, including heat-related rhabdomyolysis (Naik & Haywood, 2015; Kotila, 2016) . These complications are nevertheless extremely rare and, unlike SCD, the carrier status does not fulfil the criteria required of a medical condition to justify NBS. However, it is reliably identified by the testing and can be considered as by-product of NBS screening. The identification of carriers is a potential instrument for future disease control (Roberts & de Montalembert, 2007; Jans et al, 2012; Piel, 2016) . According to the patient representative (JJ), most carriers would like to know about their future risk of having an affected baby. Experiences from countries outside Europe show that parents are willing to receive this information (Ulph et al, 2014) , and a variety of strategies have been adopted for informing parents of carrier results (e.g. https://www.newbornscreening.on.ca/sites/default/file s/pdfs/final_do_i_want_to_know_my_childs_carrier_sta tus_for_parents_2015.pdf).
There was consensus that parents of carriers should be informed about these test results and that families should know that a disease-causing mutation is present, as this information may affect reproductive choices in the future. The panel also considered the knowledge of carrier status an important means of increasing awareness about SCD within society. The panel agreed that reporting positive carrier results should be followed by the offer of counselling of affected families by trained staff in order to avoid confusion and anxiety. The delivery of the information should follow a well-defined standardized policy. Such counselling is timeconsuming and expensive and may not be feasible within the framework of a NBS programme. Patient organizations should be involved in the national decision-making process to define and plan such programmes.
It is important to acknowledge that in some European countries, including Germany and Switzerland, currently there are legal restrictions on reporting carrier status. The panel urges the national authorities to re-think these policies. (Hachani et al, 2011; Moat et al, 2014 Moat et al, , 2017 Daniel & Henthorn, 2015 Theberge et al, 2015; Detemmerman et al, 2017) . There was consensus that new methods should be demonstrated to be at least as sensitive and as specific as HPLC and CE before they be adopted for routine screening. Automated high-throughput methods are advisable for screening of large populations. The English NHS laboratory handbook can serve as a guide for other countries (NHS 2017).
Consensus on NBS for SCD in Europe
Consensus statements
7a. High performance liquid chromatography (HPLC), capillary electrophoresis (CE), isoelectric focusing (IEF) and tandem mass spectrometry (MS/MS) are appropriate methods for NBS for SCD. 7b. New methods currently being tested should prove to be as specific and sensitive as HPLC and CE before being implemented on a larger scale.
What is the recommended procedure after a positive screening result? The approach to a first positive (presumptive SCD) screening result varies among the European countries and there were detailed discussions on the appropriate procedure after a positive screening result. The panel agreed that there is a distinction between "best practice" and "acceptable practice" in different settings.
NBS for SCD from dried blood spot samples After a first-tier screening test indicates presumptive SCD, the "best practice" is to re-test with a fresh punch using a different method on the same sample and to subsequently confirm the positive screening result with one of the two initial tests or with a third method on a second sample. Second-tier testing aims to ensure that the right sample was tested as errors may emerge from the automated punching procedure using dried blood spot cards. In addition, it aims to increase the probability that the variant haemoglobin identified by the first-tier method is HbS, because definitive identification of HbS in newborn samples can only be obtained by DNA-or mass spectrometry-based methods. Confirmatory testing aims to make a diagnosis, given that screening is, by definition, not diagnostic.
It is "acceptable" to use the same method on a re-punch of the same sample if no second-tier screening method is available and to confirm the screening result with a second method on a second sample to make a diagnosis. Diagnosis should be confirmed by the end of the second month of life to ensure that penicillin prophylaxis is started in a timely way.
NBS for SCD from cord blood and venous samples After a first-tier screening test indicates presumptive SCD, it is necessary to confirm the positive screening result and the identity of HbS with another method on a second sample.
Carrier identification "Best practice" after a first-tier screening test indicates HbS heterozygosity is to re-test with a fresh punch using another method on the same sample. "Acceptable practice" is to use the same method on a fresh punch of the same sample. Confirmatory testing from a second sample is not recommended in presumptive carriers.
Please note: one expert (MJB) found a single positive screening test sufficient to proceed to confirmatory testing from another sample with another method. It appeared that there are regional differences in terms of the variety of haemoglobin variants found in NBS. While some laboratories reported a significant prevalence of haemoglobins with biophysical properties similar to HbS, other laboratories rarely or never observed haemoglobins migrating like HbS in HPLC, CE or IEF. This finding should be taken into consideration and included in risk assessment of protocols when the local decision on methods is made.
The appropriate communication of positive test results is of fundamental importance to reduce fear and anxiety in the families and to avoid stigmatization of the baby. Results should thus reflect the testing strategy and be communicated in a standardized way. Consensuses on specific issues raised during the conference Which blood specimens are recommended/acceptable for screening? All kinds of blood specimens from the baby are appropriate for newborn screening (Nennstiel-Ratzel et al, 2011; NHS 2017 ).
Do we need additional guidelines regarding NBS for SCD?
The panel agreed that current NBS guidelines are appropriate to ensure reliable SCD screening results. Critical issues include prematurity, transfusions and maternal contamination in case of screening from cord blood. If a newborn should receive transfusions, re-screening 3 months after the last transfusion is indicated (Nennstiel-Ratzel et al, 2011; NHS 2017) .
Which false-negative and which false-positive rates are acceptable? The panel agreed that false-negative and false-positive rates should be as low as possible. The screening programme should thus be under constant review, e.g. by external quality assessment services, to constantly improve its quality.
Conclusions
Sickle cell disease is becoming a priority for European Health Care Systems. NBS enables a child to be diagnosed with SCD before presenting with symptoms and provides an opportunity to ensure early entry into a comprehensive care programme. The increased burden of SCD in Europe and the growing interconnections among European Health Care Systems raise the need for a common approach to NBS. This panel recommends universal NBS in all countries participating in the conference, collection of data on clinical outcomes through setting up of registries and development of shared clinical protocols for comprehensive care of all affected newborns. Raising public awareness about SCD is recommended, as well as focused education about the condition for health care workers, allied professionals, managers and commissioners of health care systems.
Statement on levels of evidence
The authors would like to emphasize that the level of evidence for most of the following recommendations is "expert opinion". Nevertheless, all questions have been discussed very carefully and all recommendations were made in all conscience.
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